Stevanato Group SpA

Stevanato Group SpA(STVN)の株式分析

$19.490

-0.010 (-0.05%)終値時点

Loading chart…
高値
19.765
始値
19.460
出来高加重平均価格
19.50
出来高
403.47K
時価総額
5.11B
安値
19.240
売買代金
7.87M
EV/EBITDA(TTM)
17.07

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

www.stevanatogroup.com

AI分析 of Stevanato Group SpA (STVN)

買い

Stevanato Group (STVN) is a good buy right now at $19.49, especially considering the recent earnings report showing a 7.9% year-over-year revenue growth and a gross margin improvement to 28.7%. The forward P/E ratio of 29.15 suggests the stock is reasonably valued given its growth potential. However, the main risk lies in the company’s execution risks around ramping new capacity, which could impact future performance.

バリュエーション指標

Stevanato Group SpA(STVN)の現在の予想PERは29.15で、5年平均は35.39です。

予想PER

適正
5年平均 P/E
35.39
現在のP/E
29.15
割高
44.70
割安
26.08

予想EV/EBITDA

適正
5年平均 EV/EBITDA
19.11
現在のEV/EBITDA
17.07
割高
23.13
割安
15.08

予想PSR

適正
5年平均 P/S
4.80
現在のP/S
3.85
割高
5.86
割安
3.74

Alphio AI による STVN の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%STVN

$30.64

シナリオ価格

基

基本

基本 · 50%STVN

$26.84

シナリオ価格

弱

弱気

弱気 · 25%STVN

$25.76

シナリオ価格

STVN を保有するクジラ

S

Stevanato Holding S.R.L.

+ を保有STVN

-1.57%

3か月リターン

C

Conestoga Capital Advisors, LLC

+ を保有STVN

-5.27%

3か月リターン

イベントタイムライン

2026-08-04 (ET)

07:00:00

Company Narrows 2026 Revenue View to EUR1.26B-EUR1.28B

07:00:00

Stevanato Reports Q2 Revenue of €302.0M

2026-07-30 (ET)

08:00:00

Stevanato Group Receives Marketing Authorization for Alina Injector in Europe

2025-12-01 (ET)

16:40:00

Morgan Stanley Rates Stevanato Group Equal Weight with $24 Price Target, Downgraded from $26

2025-11-06 (ET)

06:59:13

Stevanato Group projects adjusted EPS of EUR0.50-EUR0.54 for 2025

ニュース

STVN のよくある質問 — Alphio AI が回答

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Stevanato Group (STVN) is a good buy right now at $19.49, especially considering the recent earnings report showing a 7.9% year-over-year revenue growth and a gross margin improvement to 28.7%. The forward P/E ratio of 29.15 suggests the stock is reasonably valued given its growth potential. However, the main risk lies in the company’s execution risks around ramping new capacity, which could impact future performance.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める